Publications
Detailed Information
Kill rates of preserved and preservative-free topical 8-methoxy fluoroquinolones against various strains of Staphylococcus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyon, Joon Young | - |
dc.contributor.author | Eser, Ilker | - |
dc.contributor.author | O`Brien, Terrence P. | - |
dc.date.accessioned | 2012-06-29T06:54:09Z | - |
dc.date.available | 2012-06-29T06:54:09Z | - |
dc.date.issued | 2009-09 | - |
dc.identifier.citation | JOURNAL OF CATARACT AND REFRACTIVE SURGERY; Vol.35 9; 1609-1613 | ko_KR |
dc.identifier.issn | 0886-3350 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77972 | - |
dc.description.abstract | PURPOSE: To assess the kill rates of preserved and preservative-free 8-methoxy fluoroquinolones and benzalkonium chloride (BAC) against isolates of Staphylococcus aureus and coagulase-negative Staphylococcus (CNS) species. SETTING: Bascom Palmer Eye Institute, Miami, Florida, USA. METHODS: Ocular and standard isolates of S aureus and CNS were inoculated with saline, 0.005% BAC, gatifloxacin 0.3% containing 0.005% BAC (Zymar), or BAC-free moxifloxacin 0.5% (Vigamox) at 37 degrees C. Bacterial viability was assessed after 15 minutes, 30 minutes, and 60 minutes. RESULTS: Thirteen isolates of S aureus and 5 isolates of CNS were used. The mean initial load of bacterial inoculum was 5.45 log colony-forming units (CFU)/mL +/- 0.37 (SD). Saline did not affect the density of staphylococci; BAC significantly decreased the staphylococci count to a mean of 3.80 +/- 0.32 log CFU/mL at 60 minutes (P<.05). Gatifloxacin 0.3% reduced the number of staphylococci significantly more than moxifloxacin 0.5% at 15 minutes (mean 0.47 +/- 1.12 log CFU/mL versus 4.55 +/- 0.60 log CFU/mL), 30 minutes (mean 0.07 +/- 0.31 log CFU/mL versus 3.82 +/- 1.07 log CFU/mL), and 60 minutes (mean 0.00 +/- 0.00 log CFU/mL versus 2.75 +/- 1.29 log CFU/mL) (P<.005). Gatifloxacin 0.3% completely eradicated most S aureus (10/13) and CNS (3/5) isolates at 15 minutes; moxifloxacin 0.5% did not achieve complete kill in any S aureus isolate (13/13) or in most CNS isolates (4/5) at 60 minutes. CONCLUSION: The commercial formulation of gatifloxacin 0.3% containing BAC 0.005% completely eradicated staphylococcal isolates more rapidly than the BAC-free formulation of moxifloxacin 0.5% or BAC 0.005% alone. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE INC | ko_KR |
dc.title | Kill rates of preserved and preservative-free topical 8-methoxy fluoroquinolones against various strains of Staphylococcus | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 현준영 | - |
dc.identifier.doi | 10.1016/j.jcrs.2009.04.036 | - |
dc.citation.journaltitle | JOURNAL OF CATARACT AND REFRACTIVE SURGERY | - |
dc.description.citedreference | Baudouin C, 2008, ACTA OPHTHALMOL, V86, P716, DOI 10.1111/j.1755-3768.2008.01250.x | - |
dc.description.citedreference | Moshirfar M, 2007, OPHTHALMOLOGY, V114, P686, DOI 10.1016/j.ophtha.2006.08.038 | - |
dc.description.citedreference | Blondeau JM, 2007, J CHEMOTHERAPY, V19, P146 | - |
dc.description.citedreference | Kowalski RP, 2006, AM J OPHTHALMOL, V142, P730, DOI 10.1016/j.ajo.2006.06.006 | - |
dc.description.citedreference | Schlech BA, 2005, SURV OPHTHALMOL, V50, pS64, DOI 10.1016/j.survophthal.2005.05.005 | - |
dc.description.citedreference | Herretes S, 2005, AM J OPHTHALMOL, V140, P737 | - |
dc.description.citedreference | Durrie DS, 2005, J OCUL PHARMACOL TH, V21, P236 | - |
dc.description.citedreference | Romanowski EG, 2005, AM J OPHTHALMOL, V139, P867, DOI 10.1016/j.ajo.2005.01.021 | - |
dc.description.citedreference | Wallin T, 2005, J CATARACT REFR SURG, V31, P735, DOI 10.1016/j.jcrs.2004.10.057 | - |
dc.description.citedreference | Donnenfeld E, 2005, CURR MED RES OPIN, V21, P643, DOI 10.1185/030079904X5959 | - |
dc.description.citedreference | KOWALSKI RP, 2005, EXPERT REV ANTI-INFE, V3, P131 | - |
dc.description.citedreference | Kowalski RP, 2003, AM J OPHTHALMOL, V136, P500, DOI 10.1016/S002-9394(03)00294-0 | - |
dc.description.citedreference | Callegan MC, 2003, ADV THER, V20, P246 | - |
dc.description.citedreference | Tungsiripat T, 2003, AM J OPHTHALMOL, V136, P76, DOI 10.1016/S0002-9394(02)02280-8 | - |
dc.description.citedreference | Pushker N, 2002, J REFRACT SURG, V18, P280 | - |
dc.description.citedreference | Lu T, 2001, ANTIMICROB AGENTS CH, V45, P2703, DOI 10.1128/AAC.45.10.2703-2709.2001 | - |
dc.description.citedreference | Noecker R, 2001, ADV THER, V18, P205 | - |
dc.description.citedreference | Fukuda H, 2001, ANTIMICROB AGENTS CH, V45, P1649 | - |
dc.description.citedreference | Huczko E, 2000, INT J ANTIMICROB AG, V16, P401 | - |
dc.description.citedreference | Dantas PEC, 2000, CORNEA, V19, P353 | - |
dc.description.citedreference | Blondeau JM, 2000, INT J ANTIMICROB AG, V14, P45 | - |
dc.description.citedreference | Han DP, 1996, AM J OPHTHALMOL, V122, P1 | - |
dc.description.citedreference | SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P639 | - |
dc.description.citedreference | SCHEIN OD, 1989, CORNEA, V8, P281 | - |
dc.description.citedreference | ORMEROD LD, 1987, OPHTHALMOLOGY, V94, P1322 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.